Statement from Acting FDA Commissioner Ned Sharpless, M.D., on policy advancements to help bring interchangeable biosimilars to market

FDA announces final guidance on the pathway for “interchangeable” biologics, which may be substituted without the involvement of the prescriber.

Original source: http://www.fda.gov/news-events/press-announcements/statement-acting-fda-commissioner-ned-sharpless-md-policy-advancements-help-bring-interchangeable

Related Posts